Avemar inhibe el crecimiento de carcinoma mamario en xenotransplante humano y de rata, comparablemente a los tratamientos endocrinos

Abstracto
Background: An in vitro study demonstrated that Avemar increased the effect of Tamoxifen on MCF7 (ER+) mammary carcinoma cells. Methods: MXT (ER+) mouse mammary tumor tissue was transplanted s.c. into BDF1 mice. The tumor bearing animals were treated p.o. with Avemar. Then the most effective Avemar dose (3.0 g/kg), Tamoxifen (0.5 mg/kg s.c.), Examestane (10 mg/kg i.p.) and Anastrasol (5 mg/kg i.p.) monotherapies and their combinations with Avemar was compared. All treatments were given once daily, for 10 days, starting 7 days after the tumor transplantation. The same experimental schedule was repeated using T47/D (ER+) human breast carcinoma cell lines transplanted into C.B-17/Icr-scid/scid mouse. Finally, the growth of T47/D and MDA-MB-231 (ER-) xenografts treated by Avemar was compared. Tumor volume was measured up to 25 days after transplantation in MXT and 55 days in xenograft. Results: In MXT model all monotherapies and combinations led to retardation of tumor growth. Combination of Avemar with any of the endocrine treatment enhanced the efficacy compared to endocrine monotherapy. Out of the four monotherapies the best result was achieved by Avemar (50% inhibition). The combination of Avemar with Examestane increased the tumor growth inhibition to 60.4% compared to control. The other treatments did not exceed the effect of Avemar monotherapy. In xenograft model Avemar produced 50% tumor growth inhibition compared to control and was more effective than the other treatments Examestane (26%), Anastrasol (25%) or Tamoxifen (42%). Combined treatment with Avemar always improved efficacy within the range of 3-10%. Avemar showed similar efficacy when T47/D (49%) and MDA-MB-231 (52%) xenografts were compared. Conclusions: The tumor growth inhibitory effect of Avemar on ER positive MXT mouse breast carcinoma as well as in T47/D xenograft models are comparable (equal or better) to standard endocrine treatments. Avemar certainly did not reduce the effect of endocrine treatments. The antitumor activity of Avemar did not depend on the estrogen receptor status.
Palabras clave
Descargar la publicación en formato pdf:
EN FR
Centro de investigación

Eficacia de un nutrimento médico en el tratamiento de cáncer

Autores
Publicado en:
Fecha
Tipo del artículo
Abstracto
Varios productos naturales se utilizan como suplementos nutricionales por los pacientes oncológicos muchas veces sin consultar con sus médicos. Es importante saber cuáles de estos productos son eficaces contra el cáncer y cáles son ineficaces. También es fundamental definir los mecanismos del productos naturales, especialmente con respeto al prevención del cáncer. El objeto del artículo es revisar el uso de aquel producto; el extraco del germen de trigo fermentado (Avemar) en el tratamiento del cáncer.
Palabras clave
Descargar la publicación en formato pdf:
EN FR
Leer el artículo en
Centro de investigación

Estudios sobre la seguridad del extracto de germen de trigo fermentado estandardizado

Abstracto
Avemar pulvis es un polvo compuesto de un extracto acuoso del germen de trigo fermentado, con agentes astringentes como la maltodextrina y el dióxido de silicio coloidal estandardizado en sobre 200 μg/g de la 2,6 dimetoxi-p-benzoquinona, que es un componente natural. Los resultados del estudios clínicos y toxicológicos del producto demostraron su seguridad para su uso como un alimento dietético en los Estados Unidos. Avemar pulvis ha sido usado desde 1998 y está aprobado también en la República Checa, Bulgaria y Rumania como “alimento dietético para usos médicos especiales” para pacientes con cáncer. Los estudios de toxicidad aguda y subaguda en que Avemar fue administrado por vía oral mostraron que en sobre dosis (2000 hasta 3000mg/kg por peso corporal /día) la dosis diaria recomendada no causó efectos adversos. La sustancia testada no mostró ninguna evidencia de mutagenicidad o genocidad ni in vitro ni in vivo. En estudios clínicos el uso de Avemar pulvis en dosis de 8,5 g/día como suplemento al tratamiento farmacológico en pacientes con cáncer, no mostró ningún efecto tóxico pero redujo unos efectos secundarios de la quimioterapia. En general, se concluyó que el uso de Avemar pulvis en alimentos dietéticos no se espera que cause efectos adversos en la dosis recomendada.
Palabras clave
Descargar la publicación en formato pdf:
EN FR ES
Leer el artículo en
Centro de investigación

Efecto de Avemar – un extracto de germen de trigo fermentado - en la Artitis Reumatoide. Datos prelinminados

Abstracto
OBJECTIVE: To investigate the effect of the fermented wheat germ extract (Avemar) in patients with severe rheumatoid arthritis (RA). METHODS: Fifteen female RA (Steinbrocker II-III) patients, who had unsuccessfully tried two different DMARD treatments, were enrolled in an open-label, 1-year long, pilot clinical study. DMARD and steroid therapies were recorded and continued. All patients received Avemar as additional therapy. For measurement of efficacy the Ritchie Index, the Health Assessment Questionnaire (HAQ) and the assessment of morning stiffness were applied. Patients were evaluated at baseline, 6 and 12 months. For statistical analyses the Wilcoxon test was used.RESULTS: At both 6 and 12 months, Ritchie index, HAQ and morning stiffness showed significant improvements compared with the baseline values. Dosages of steroids could be reduced in about half of the patients. No side effects of Avemar were observed. CONCLUSION:Supplementation of standard therapies with a continuous administration of Avemar is beneficial for RA patients.
Palabras clave
Descargar la publicación en formato pdf:
EN FR HU
Leer el artículo en
Centro de investigación

Recomendación de la Asociación Húngara de Cirugía Oral y Maxilofacial (Magyar Arc-, Állcsont- és Szájsebészeti Társoság) en la indicación del tratamiento de apoyo con Avemar

Abstracto
The Hungarian Association of Oral and Maxillofacial Surgeons (Magyar Arc-, Állcsont- és Szájsebészeti Társaság) has reviewed the research results related to Avemar and issued its opinion as follows: For patients suffering from head- and neck tumors - primarily malignant tumorous diseases of the oral cavity, the progression of the disease can be slowed significantly, the five-year survival rate increased considerably, the quality of life improved, and the oxidative stress on the patients reduced by the long-term application of the supplementary formula Avemar. The Association considers the supportive treatment with the formula Avemar as an important part of the complex therapeutic protocols applied in stages II, III and IV of malignant tumorous diseases of the oral cavity.
Palabras clave
Descargar la publicación en formato pdf:
EN HU
Leer el artículo en
Centro de investigación

Avemar como tratamiento de apoyo en el cáncer

Autores
Publicado en:
Fecha
Tipo del artículo
Abstracto

An extract of fermented wheat germ, Avemar, was developed during the 1990s by Hungarian biochemist Mate Hidvegi, Ph.D. Initially, Avemar was available as an over-the-counter dietary supplement, but in 2002 the product was registered as a medical nutriment with an indication for use in cancer treatment by the Hungarian National Institute of Food Safety and Nutrition.

“It is not like shark cartilage or cat’s claw or other such products, which may or may not be good, but which are not official cancer treatments. In Hungary, Avemar has become an accepted part of cancer treatment,” Dr. Hidvegi said in an interview. For example, the Hungarian Association of Oral and Maxillofacial Surgeons has issued an official statement indicating that Avemar should be included in the treatment protocol for squamous cell carcinoma of the oral cavity.

>>An extract of fermented wheat germ has shown immunomodulatory effects in vivo and tumor-supressive effects in vitro.
>>Studies have suggested that the proprietary formulation Avemar may be beneficial in certain types of cancer.

Palabras clave
Descargar la publicación en formato pdf:
EN

Avemar, un alimento dietético con efectos anticancerosos, aprobados

Autores
Publicado en:
Fecha
Tipo del artículo
Abstracto
Avemar is concentrated and extracted from fermented wheat germ via a patented process and has been shown in cell, animal, and human clinical studies to have potent anti-cancer and immune system-modulating effects. Extensive published research supports the use of Avemar both as a medicament in its own right and as an adjuvant to conventional cancer therapy. (1-3) Avemar has proven effective against all cancer cell lines tested, including breast, prostate, lung, pancreatic, lymphoma, and leukemia. It has been shown to have both cancer-preventive and anti-metastatic properties in animal studies and has demonstrated highly significant therapeutic effects in controlled human trials against primary colorectal cancer, Stage III melanoma, and Stages III and IV oral cancer.
Avemar also has been shown to reduce side effects of conventional cytotoxic cancer therapy, such as suppression of immune function, and to improve quality of life in cancer patients. Developed in Hungary and widely used throughout Europe and parts of the Middle East and Asia, Avemar is newly available in the United States and now rapidly gaining wider use following its recent GRAS (Generally Recognised As Safe) designation.
Palabras clave
Descargar la publicación en formato pdf:
EN FR

Avemar

Abstracto
Palabras clave
Descargar la publicación en formato pdf:
EN DE

Avemar, un extracto de germen de trigo fermentado non-tóxico, induce apoptosis e inhibe ribonucleotid reductasa en celulas de leucémicas promieloíticas humanas HL-60

Abstracto
Avemar (MSC) is a nontoxic fermented wheat germ extract demonstrated to significantly improve the survival rate in patients suffering from various malignancies. We investigated its effects in human HL-60 promyelocytic leukemia cells. After 24, 48, and 72 h of incubation, Avemar inhibited the growth of HL-60 cells with IC50 values of 400, 190, and 160 µg/ml, respectively. Incubation with MSC caused dose-dependent induction of apoptosis in up to 85% of tumor cells. In addition, Avemar attenuated the progression from G2-M to G0-G1 phase of the cell cycle and was also found to significantly reduce the in situ activity of ribonucleotide reductase, the key enzyme of de novo DNA synthesis. We conclude that Avemar exerts a number of beneficial effects which could support conventional chemotherapy of human malignancies.
Palabras clave
Descargar la publicación en formato pdf:
EN FR
Leer el artículo en
Centro de investigación

El extracto milagroso contra cáncer que no hace daño a las células sanas

Autores
Publicado en:
Fecha
Tipo del artículo
Abstracto
Cancer treatment has come a long way since the use of mustard gas derivatives in the early 1900s—or has it? When doctors discovered during WorldWar I that mustard gas destroyed bone marrow, they began to experiment with it as a way to kill cancer cells. Although they had little success with the mustard gas, it did pave the way for modern chemotherapy—which involves the most toxic and poisonous substances anyone deliberately puts in his body. These treatments kill much more than cancer cells— they have a devastating effect even on healthy ones. Sometimes it seems as if only a miracle could provide a cure that’s both safe and effective. And a miracle is just what Dr. Mate Hidvegi believed he found when he patented Avemar, a fermented wheat germ extract. Studies have shown that Avemar reduces cancer recurrence, cuts off the cancer cells’ energy supply, speeds cancer cell death, and helps the immune system identify cancer cells for attack.
Palabras clave
Descargar la publicación en formato pdf:
EN FR